New cancer drug trial halted after just 3 patients

NCT ID NCT07159828

Terminated Disease control Sponsor: Axion Bio, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 participants, so we have very little information about its safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AXN-2510 (a bispecific antibody that blocks PD-L1 and inhibits VEGF)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This was a very early, small Phase 1 trial that was terminated after only 3 participants. It is too early to know if the drug is safe or effective, and many early-stage cancer drugs never reach patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Carolina BioOncology

Huntersville, North Carolina, 28078, United States
NEXT Houston

Houston, Texas, 77054, United States
NEXT San Antonio

San Antonio, Texas, 78229, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
New Experimental Therapeutics (NEXT) Oncology - Houston

Houston, Texas, 77054, United States
New Experimental Therapeutics of San Antonio - NEXT Oncology

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at Mary Crowley

Dallas, Texas, 75251, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.